Multibagger Stocks: Fredun Pharmaceuticals has given surprising returns to investors in the last few years. It has become one of the multibagger companies in the pharma sector. Nine years ago the share price of this company was only Rs 12.50, whereas today it has increased to Rs 1,425. That means, it has given a return of about 11,300% in just 9 years. Even in the last six months, this stock has seen tremendous growth.

What does the company do?

Fredun Pharmaceuticals is an Indian formulation manufacturing company, established in 1987. The company’s presence extends to Latin America, South-East Asia, CIS countries, Africa and MENA (Middle East and North Africa). Along with medicines, this company has also recently taken steps towards starting India’s first neutral online pet marketplace by acquiring pet tech platform “Wagr”.

If an investor had invested Rs 1 lakh in this company 5 years ago, today its value would have reached Rs 1.14 crore. In this way, this stock has proved to be a wealth creation machine for investors.

Financial position and shareholding

Promoter Holding (June 2025): 48.93%
Public Holding: 51.07%
Bank of India holds 1.59% (75,000 shares) of the company.

The company’s shares had registered the highest annual gain of 223% in 2018. If this stock continues to grow at the same pace in 2025, then it could prove to be the strongest financial year after 2020.

Also read: Did TCS lay off 20 thousand staff instead of 12 thousand? Why did the company hide the figures, HR’s answer has come

Disclaimer: (The information provided here is being given for information only. It is important to mention here that investment in the market is subject to market risks. Always take expert advice before investing money as an investor. ABPLive.com never advises anyone to invest money here.)

Trump pharma tariff: The Indian stock market declined on Tuesday on Tuesday, the fifth day of tension between Iran and Israel. Today the Nifty slipped below 24,900 points. All the sectors closed on the red mark except IT. The Sensex fell 212 points to close at 81,583, while the Nifty fell 50 93 points to close at 24,853. The Nifty midcap and smallcap index also closed down by 0.5 percent.

Pharma companies decline in shares

Today, the shares of pharma companies also declined by 4 percent as US President Donald Trump says that he is going to impose tariffs very soon on the pharma sector. Today, after this announcement of Trump, Aurobindo Pharma shares fell 4 percent to Rs 1,094.4. Similarly, lupine, granules and Natco Pharma recorded a decline of 3-4 percent.

The share price of Laus Labs, Dr. Reddy’s, Sun Pharma and Glenmark Pharma has also declined by 2-3 percent. Amid this decline in shares of pharma companies, the Nifty Pharma Index saw a weakness of 2.2 percent. Out of 20, 19 stocks were trading in red mark.

Trump threatened to put tariff on pharma sector

In April, Trump announced to impose reciperoot tariffs on 60 countries of the world except the pharma sector. During that time, Trump had said that tariffs will be installed at the level on the pharma sector, which you have never seen before. Actually, Trump wants to put a tariff on pharmaceuticals products because he feels that America will benefit from it. If the dependence on imports is low, then the production of medicines in the US will increase. With this, Americans will also get medicines cheaper.

Trump’s decision affects India

Trump’s decision is going to have a big impact on India because India is one of the biggest suppliers of medicines for America. If Trump puts tariffs on pharmaceutical products, then it will cause great damage to India’s pharma sector. In 2024, India exported US $ 12.72 billion pharmaceutical products to the US.

Also read:

Government ready to sell its stake in these 5 banks, amazing boom in shares; Buying competition